๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuzhou
Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 9 Guangzhou 7 Tianjin 5 Fuzhou 5 Zhengzhou 4
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing9 Guangzhou7 Tianjin5 Fuzhou5 Zhengzhou4
All 32 locations
Target enrolment
to

Trials with a site in Fuzhou

5 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
NCT07206264Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
45
Fuzhou, Shijiazhuang, Harbin, Jinan, Tianjin
2025-10
Active, closed
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
BeiGene
Phase 1/2
125
Hefei, Beijing, Fuzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Haikou
2022-09-05
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
NCT05294731B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BeiGene
Phase 1/2
146
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Nanyang
2022-05-06
Active, closed
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
NCT04718883Mantle Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
59
Beijing, Fuzhou, Guanzhou, Zhengzhou, Nanjing, Shanghai, Tianjin, Hangzhou
2021-01-13
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Janssen Research & Development, LLC
Phase 3
700
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shanxi, Suzhou
2013-09-09
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5 of those studies with a site in Fuzhou that also match the filters currently applied.

How many clinical trials are recruiting in Fuzhou?

2 of the 5 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fuzhou), 5 studies
PhaseStudiesRecruitingShare
Phase 1/22140%
Phase 22040%
Phase 31120%

Most active sponsors

Lead sponsors with the most studies (Fuzhou)
Lead sponsorStudiesRecruiting
BeiGene21
Janssen Research & Development, LLC11
Shanghai Ming Ju Biotechnology Co., Ltd.10
Tianjin Medical University Cancer Institute and Hospital10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.